MICHAEL MOTISE-PACIER: Open Payments
NPI 1659822849 · WOODSTOCK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,853 in 95 payments from 12 companies in 2025. Trend: 2023 $1,499 · 2024 $1,826 · 2025 $1,853
Food & beverage: $1,849Education: $4
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $539 |
| Neurocrine BioSciences, Inc. | 12 | $300 |
| Teva Pharmaceuticals USA, Inc. | 11 | $285 |
| Otsuka America Pharmaceutical, Inc. | 12 | $201 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $152 |
| Janssen Pharmaceuticals, Inc | 5 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $84 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $68 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $24 |
Products named: VRAYLAR, INGREZZA, AUSTEDO XR, CAPLYTA, REXULTI, INVEGA SUSTENNA, TRINTELLIX, REJOYN.
Industry payments across NY — which companies pay providers there.
